Nefiracetam powder (77191-36-7)

Nefiracetam powder (77191-36-7) video

 

Nefiracetam powder Base Information

Name	Nefiracetam powder
CAS	77191-36-7
Purity	98%
Chemical name	Nefiracetam  77191-36-7 N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide ,Translon ,DM 9384
Synonyms	(2-(2-Oxopyrrolidin-1-yl)-N-(2,6-dimethylphenyl)-acetamide), DM-9384
Molecular Formula	C14H18N2O2
Molecular Weight	246.3 g/mol
Melting Point	151-155°C
InChI Key	NGHTXZCKLWZPGK-UHFFFAOYSA-N
Form	Solid
Appearance	white to off-white powder
Half Life	3-5 hours
Solubility	Soluble to 100 mM in DMSO and to 100 mM in ethanol
Storage Condition	Store at RT
Application	Nefiracetam is an organooxygen compound and an organonitrogen compound. It derives from an alpha-amino acid.Its Nootropics
Testing Document	Available

 

Nefiracetam powder General Description

Nefiracetam powder is considered to be much more potent than Piracetam. As a nootropic, it helps increase attention span, alertness, cognition, learning and boosts memory.Nefiracetam is used as a prescription drug in Japan. And as a supplement in the United States.It is similar in structure to Piracetam with a phenyl group and two methyl groups added to the amine of Piracetam. Nefiracetam, like all racetam nootropics, has a pyrrolidone nucleus at its core. The structure of Nefiracetam is similar to Aniracetam

 

Nefiracetam powder (77191-36-7) History

Nefiracetam was developed by Daiichi Seiyaku in the 1990’s as a treatment for cerebrovascular disorders. In 1999, Nefiracetam was in phase II clinical trials in the USA for treatment of cognition problems as a consequence of stroke, and Alzheimer’s type dementia.Japan-based pharmaceutical company Daiichi Seiyaku developed Nefiracetam in the late 1990’s as a derivative of Piracetam.Nefiracetam is fat-soluble while Piracetam is water-soluble. Fat-soluble molecules cross the blood-brain barrier more easily than water-soluble molecules.

Both Nefiracetam and Piracetam are cognitive enhancers. And both have neuroprotective qualities. Both racetams are able to improve learning and memory. And both are able to prevent brain damage.

 

Nefiracetam (77191-36-7) Mechanism Of Action

Nefiracetam has additional benefits not shared with Piracetam. Nefiracetam can reduce anxiety and depression. And exhibits several other memory enhancing qualities over Piracetam.Nefiracetam increases the amount of time calcium channels in neurons remain open. Tied to protein kinase A (PKA) and the Gi alpha subunit (Gi/o protein), signaling is enhanced in the neuroreceptor independent of the synapse. This calcium channel pathway is critical for long-term potentiation (LTP) and the formation of long-term memories.Nefiracetam also potentiates protein kinase C alpha (PKCα) which is involved in long-term potentiation (LTP). PKCα is dependent on glutamate signaling.And Nefiracetam activates Ca2+/calmodulin-dependent protein kinase II (CaMKII)which is critical in memory formation. Again dependent on glutamate signaling.Finally, Nefiracetam potentiates acetylcholine receptors in the hippocampus which encourages glutamate release and LTP. Piracetam does not share this memory enhancing quality.The bottom-line is Nefiracetam seems to be a much more potent memory enhancer that the original nootropic Piracetam.

 

Nefiracetam (77191-36-7) Application

Neuroprotection: Nefiracetam helps control NMDA signaling which protects against excessive glutamate levels. Glutamate is powerful excitatory neurotransmitter. Too much glutamate damages neurons and the entire brain.

Neurotransmitters: Nefiracetam modulates GABA levels in the brain. Reducing GABA when it’s too high, and increasing GABA levels if they’re too low. Producing a calm-like focus and reducing anxiety. Nefiracetam prolongs the opening of calcium channels. Keeping neurotransmitters active longer. Improving memory formation and recall.

Acetylcholine: Nefiracetam potentiates nicotinic acetylcholine receptors. Boosting the release of GABA and glutamate. Producing a calming effect while improving neuroplasticity and boosting learning and memory.

Nefiracetam (DM-9384, N-(2, 6-dimethylphenyl)-2-(2-oxopyrrolidine-1-yl)-acetamide) is in the racetam-family of nootropic compounds. It is a fat-soluble nootropic.

The racetam-class of nootropics have a pyrrolidone nucleus at their core. An Nefiracetam is a cholinergic compound, meaning it affects acetylcholine levels in the brain.

Nefiracetam is used as a prescription drug in Japan. It is sold as an over-the-counter, unrestricted compound in the United States. But not as a dietary supplement.One of the most recent synthetic nootropic compounds, it is known as a cognitive enhancer. And is known for its anxiolytic, or anti-anxiety effects.

 

Nefiracetam (77191-36-7) More research

Nefiracetam boosts brain health and function in several ways. But two in particular stand out.

Nefiracetam enhances memory. In several studies and clinical trials, researchers have noted Nefiracetam’s anti-amnesia effects. And they’ve arrived at this observation by noting Nefiracetam interacting with individual acetylcholine receptors in the brain.

One study conducted at the Albert Einstein Healthcare Network in Philadelphia worked with older rabbits. Researchers use a technique called the “nictitating membrane (NM)/eyeblink response” in rabbits which is used in the lab to study age-related memory disorders.

In this case, the team used Nefiracetam to study its effect on retention and relearning. The scientists administered 5, 10 or 15 mg/kg of Nefiracetam to 34 “retired” rabbits over 15 days.

 

Nefiracetam (77191-36-7) Reference

• Crespi F. “Nefiracetam. Daiichi Seiyaku.” Current Opinion in Investigational Drugs. 2002 May;3(5):788-93.
• Malenka R.C., Kauer J.A., Perkel D.J., Nicoll R.A. “The impact of postsynaptic calcium on synaptic transmission — its role in long-term potentiation” Trends in Neurosciences Volume 12, Issue 11, p444–450, 1989
• Kim H., Han S.H., Quan H.Y., Jung Y.J., An J., Kang P., Park J.B., Yoon B.J., Seol G.H., Min S.S. “Bryostatin-1 promotes long-term potentiation via activation of PKCα and PKCε in the hippocampus.” Neuroscience. 2012 Dec 13;226:348-55.
• Moriguchi S., Han F., Shioda N., Yamamoto Y., Nakajima T., Nakagawasai O., Tadano T., Yeh JZ, Narahashi T., Fukunaga K. “Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice.” Journal of Neurochemistry. 2009 Jul;110(1):170-81
• The Ultimate Comparison Guide of Racetam Nootropics
• Best Nootropic Stack Guide: Everything You Need To Know [5 Years Experience]